PURPOSE: to report acute and late toxicity in prostate cancer patients treated by high-dose intensity-modulated radiation therapy (IMRT) with daily image-guidance. PATIENTS AND METHODS: from 06/2004-03/2008, 102 men were treated with 80 Gy IMRT with daily image-guidance. The risk groups were as follows: low, intermediate, and high risk in 21%, 27%, and 52% of patients, respectively. Hormone therapy was given to 65% of patients. Toxicity was scored according to the CTC scale version 3.0. RESULTS: median age was 69 years and median follow-up was 39 months (range, 16-61 months). Acute and late grade 2 gastrointestinal (GI) toxicity occurred in 2% and 5% of patients, respectively, while acute and late grade 3 GI toxicity was absent. Grade 2 and 3 pretreatment genitourinary (GU) morbidity (PGUM) were 15% and 2%, respectively. Acute grade 2 and 3 GU toxicity were 43% and 5% and late grade 2 and 3 GU toxicity were 21% and 1%, respectively. After multiple Cox regression analysis, PGUM was an independent predictor of decreased late ≥ grade 2 GU toxicity-free survival (hazard ratio = 9.4 (95% confidence interval: 4.1, 22.0), p < 0.001). At the end of follow-up, the incidence of late grade 2 and 3 GU toxicity decreased to 7% and 1%, respectively. CONCLUSION: GI toxicity rates after IMRT with daily image-guidance were excellent. GU toxicity rates were acceptable and strongly related to PGUM.
PURPOSE: to report acute and late toxicity in prostate cancerpatients treated by high-dose intensity-modulated radiation therapy (IMRT) with daily image-guidance. PATIENTS AND METHODS: from 06/2004-03/2008, 102 men were treated with 80 Gy IMRT with daily image-guidance. The risk groups were as follows: low, intermediate, and high risk in 21%, 27%, and 52% of patients, respectively. Hormone therapy was given to 65% of patients. Toxicity was scored according to the CTC scale version 3.0. RESULTS: median age was 69 years and median follow-up was 39 months (range, 16-61 months). Acute and late grade 2 gastrointestinal (GI) toxicity occurred in 2% and 5% of patients, respectively, while acute and late grade 3 GI toxicity was absent. Grade 2 and 3 pretreatment genitourinary (GU) morbidity (PGUM) were 15% and 2%, respectively. Acute grade 2 and 3 GU toxicity were 43% and 5% and late grade 2 and 3 GU toxicity were 21% and 1%, respectively. After multiple Cox regression analysis, PGUM was an independent predictor of decreased late ≥ grade 2 GU toxicity-free survival (hazard ratio = 9.4 (95% confidence interval: 4.1, 22.0), p < 0.001). At the end of follow-up, the incidence of late grade 2 and 3 GU toxicity decreased to 7% and 1%, respectively. CONCLUSION:GI toxicity rates after IMRT with daily image-guidance were excellent. GU toxicity rates were acceptable and strongly related to PGUM.
Authors: Daniel Vetterli; Sandrine Thalmann; Frank Behrensmeier; Ludger Kemmerling; Ernst J Born; Roberto Mini; Richard H Greiner; Daniel M Aebersold Journal: Radiother Oncol Date: 2006-04-18 Impact factor: 6.280
Authors: Jinka R Sathya; Ian R Davis; Jim A Julian; Qing Guo; Dean Daya; Ian S Dayes; Himu R Lukka; Mark Levine Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: Stephanie T H Peeters; Wilma D Heemsbergen; Wim L J van Putten; Annerie Slot; Hans Tabak; Jan Willem Mens; Joos V Lebesque; Peter C M Koper Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-15 Impact factor: 7.038
Authors: Michael Pinkawa; Martin Pursch-Lee; Branka Asadpour; Bernd Gagel; Marc D Piroth; Jens Klotz; Sandra Nussen; Michael J Eble Journal: Strahlenther Onkol Date: 2008-12-24 Impact factor: 3.621
Authors: Abrahim Al-Mamgani; Wim L J van Putten; Wilma D Heemsbergen; Geert J L H van Leenders; Annerie Slot; Michel F H Dielwart; Luca Incrocci; Joos V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-19 Impact factor: 7.038
Authors: G Goldner; R Pötter; J J Battermann; M P Schmid; C Kirisits; S Sljivic; M van Vulpen Journal: Strahlenther Onkol Date: 2012-02-22 Impact factor: 3.621
Authors: M Geier; S T Astner; M N Duma; V Jacob; C Nieder; J Putzhammer; C Winkler; M Molls; H Geinitz Journal: Strahlenther Onkol Date: 2012-02-26 Impact factor: 3.621
Authors: M Guckenberger; G Saur; D Wehner; R A Sweeney; A Thalheimer; C-T Germer; M Flentje Journal: Strahlenther Onkol Date: 2012-05-27 Impact factor: 3.621
Authors: Michael Pinkawa; Marc D Piroth; Richard Holy; Victoria Djukic; Jens Klotz; Barbara Krenkel; Michael J Eble Journal: Strahlenther Onkol Date: 2011-07-25 Impact factor: 3.621
Authors: A Singer; Y Deuse; U Koch; T Hölscher; D Pfitzmann; C Jakob; S Hehlgans; G B Baretton; A Rentsch; M Baumann; M H Muders; M Krause Journal: Strahlenther Onkol Date: 2012-11-07 Impact factor: 3.621